Coadministration of pexidartinib (a CYP3A4 inducer) with sensitive CYP3A substrates may perhaps cause serious therapeutic failures. If concomitant use is unavoidable, raise the CYP3A substrate dosage in accordance with approved solution labeling.If coadministration of CYP3A4 inhibitors with fentanyl is critical, check patients for respiratory depre